Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM<sup>®</sup>: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies.

Sánchez, Pedro; Álamo, Cecilio; Almendros, Marcos; Schlueter, Max; Tasoulas, Anastasios; Martínez, Javier

Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM^®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies.

Sánchez, Pedro; Álamo, Cecilio; Almendros, Marcos; Schlueter, Max; Tasoulas, Anastasios; Martínez, Javier.

Afiliação

Sánchez P; Hospital of Zamudio. Bizkaia Mental Health Network. Osakidetza Basque Health Service, Bilbao, Spain.
Álamo C; Faculty of Health Sciences. Department of Medicine, Deusto University, Bilbao, Spain.
Almendros M; Department of Biomedical Sciences, Alcalá University. Alcalá de Henares, Madrid, Spain.
Schlueter M; Medical Department, Laboratorios Farmacéuticos ROVI, S.A, Calle Alfonso Gómez, 45B. 28037, Madrid, Spain.
Tasoulas A; IQVIA, London, UK.
Martínez J; IQVIA, Athens, Greece.

Ann Gen Psychiatry ; 22(1): 33, 2023 Sep 02.

Article em En | MEDLINE | ID: mdl-37660132